McKesson Stock Price, News & Analysis

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have extended the deadline for political subdivisions to join the proposed opioid settlement from January 2, 2022, to January 26, 2022. New Mexico confirmed its participation, raising total states in the settlement to 43, covering all U.S. territories and Washington, D.C. The deadline to assess sufficient participation has also been moved from February 1, 2022, to February 25, 2022. The companies aim to expedite relief to affected communities and remain committed to addressing the opioid crisis.

McKesson Corporation (NYSE: MCK) has agreed to sell its Austrian operations to Quadrifolia Management GmbH. This deal includes McKesson Austria’s Herba Chemosan Apotheker-AG and Sanova Pharma GesmbH, expected to close in fiscal 2022 following regulatory approvals. CEO Brian Tyler stated this aligns with McKesson's strategy to streamline its portfolio and exit the European market, following previous agreements in the UK, France, Italy, Ireland, Portugal, Belgium, and Slovenia.

McKesson Corporation (NYSE: MCK) is hosting an Investor Day at 1:00 p.m. ET today to outline its strategy for sustainable growth. The event will cover progress in healthcare services and reaffirm commitments to expanding oncology and biopharma services. McKesson increased its fiscal 2022 Adjusted Earnings per Diluted Share guidance to $22.35-$22.95, boosted by the U.S. government's COVID-19 vaccine program. Additionally, a $4.0 billion share repurchase program was announced, highlighting a focus on shareholder value.

McKesson Corporation (NYSE: MCK) is set to host an Investor Day on December 8, 2021, from 1:00 PM to 4:00 PM ET in New York City. The event will include presentations by the leadership team, a live Q&A with CEO Brian Tyler and CFO Britt Vitalone, and discussions on the company’s progress towards sustainable growth and long-term financial outlook.

A video webcast will be available live and archived on McKesson's Investor Relations website.

Walgreens Boots Alliance (WBA) has announced its agreement to acquire the remaining 30% share of its joint venture with McKesson Corporation (MCK) in Germany, making WBA the sole owner of GEHE Pharma Handel and Alliance Healthcare Deutschland. This acquisition is part of McKesson's strategy to fully exit the European market. The transaction's financial terms were not disclosed and are subject to regulatory approval. This move aims to strengthen WBA's presence in the German pharmaceutical distribution market.

McKesson Corporation (NYSE: MCK) has released its fiscal 2022 second-quarter financial results. The earnings call is scheduled for November 1 at 4:30 PM ET, and results can be accessed on McKesson’s Investor Relations website. The company is recognized as a leader in healthcare supply chain management and has received accolades such as being named the "Most Admired Company" in its sector by FORTUNE. For further details, visit investor.mckesson.com/financials/quarterly-results.

McKesson Corporation (NYSE: MCK) has announced plans to sell its UK businesses to AURELIUS as part of its strategy to fully exit the European market. This includes the sale of entities like LloydsPharmacy and AAH Pharmaceuticals. The transaction is set to close in fiscal 2022, pending regulatory approvals. CEO Brian Tyler emphasized that this move allows for better long-term growth opportunities for the UK operations while enabling McKesson to focus on strategic investments outside Europe. This sale follows a previous agreement to divest businesses in several European countries.

The Board of Directors of McKesson Corporation (NYSE:MCK) has declared a regular dividend of 47 cents per share of common stock. This dividend will be payable on January 3, 2022, to stockholders of record as of December 1, 2021. This announcement highlights McKesson's commitment to returning value to its shareholders while maintaining its position as a leader in healthcare supply chain management and services.

Hercules Capital has appointed Pam Randhawa to its Board of Directors, effective November 1, 2021. With over 20 years in the healthcare and life sciences sectors, her background includes leadership positions at McKesson and her own firm, Empiriko Corporation. Randhawa's expertise is expected to enhance the board's capabilities as Hercules focuses on long-term growth and shareholder returns. CEO Scott Bluestein praised her contributions within the life sciences community, indicating her appointment is part of a strategy to bolster the company's leadership team.